Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines
Open Access
Abstract
Safety, efficacy, and cost-effectiveness are paramount to vaccine development. Following the isolation of rotavirus particles in 1969 and its evidence as an aetiology of severe dehydrating diarrhoea in infants and young children worldwide, the quest to find not only an acceptable and reliable but cost-effective vaccine has continued until now. Four live-attenuated oral rotavirus vaccines (LAORoVs) (Rotarix®, RotaTeq®, Rotavac®, and RotaSIIL®) have been developed and licensed to be used against all forms of rotavirus-associated infection. The efficacy of these vaccines is more obvious in the high-income countries (HIC) compared with the low- to middle-income countries (LMICs); however, the impact is far exceeding in the low-income countries (LICs). Despite the rotavirus vaccine efficacy and effectiveness, more than 90 countries (mostly Asia, America, and Europe) are yet to implement any of these vaccines. Implementation of these vaccines has continued to suffer a setback in these countries due to the vaccine cost, policy, discharging of strategic preventive measures, and infrastructures. This review reappraises the impacts and effectiveness of the current live-attenuated oral rotavirus vaccines from many representative countries of the globe. It examines the problems associated with the low efficacy of these vaccines and the way forward. Lastly, forefront efforts put forward to develop initial procedures for oral rotavirus vaccines were examined and re-connected to today vaccines.Keywords
Funding Information
- Postgraduate Research, University of the Free State, Bloemfontein South Africa (1-459-33279-1831)
This publication has 367 references indexed in Scilit:
- Environmental enteropathy: critical implications of a poorly understood conditionTrends in Molecular Medicine, 2012
- Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigenNature, 2012
- Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccineVaccine, 2012
- 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus VaccineEvolution: Education and Outreach, 2011
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension StudyEuropean Journal of Pediatrics, 2010
- Association Between Pentavalent Rotavirus Vaccine and Severe Rotavirus Diarrhea Among Children in NicaraguaJAMA, 2009
- Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segmentsArchives of Virology, 2008